Quantcast
Last updated on April 19, 2014 at 8:45 EDT

Latest Study of Tamoxifen and Raloxifene Stories

Tamoxifen Can Halve Breast Cancer Risk When Prescribed Longer
2013-06-03 13:09:55

Lee Rannals for redOrbit.com — Your Universe Online Researchers announced new findings that taking one breast cancer drug for twice the time suggested can substantially increase survival rates. The scientists said that women diagnosed with breast cancer who take tamoxifen for 10 years, rather than five years, halve their chances of dying. "These findings are extremely exciting for women who are diagnosed with the most common type of breast cancer," said Dr Julia Wilson,...

2013-04-25 19:46:09

Drinking coffee could decrease the risk of breast cancer recurring in patients taking the widely used drug Tamoxifen, a study at Lund University in Sweden has found. Patients who took the pill, along with two or more cups of coffee daily, reported less than half the rate of cancer recurrence, compared with their non-coffee drinking, Tamoxifen-taking counterparts. The team followed over 600 breast cancer patients from southern Sweden for an average of five years. Approximately 300 took...

2012-03-27 06:23:34

By the National Cancer Institute Editor's Note: The following article is part of the monthly Lifelines print series that the National Cancer Institute provides to African American news and information outlets. BETHESDA, Md., March 27, 2012 /PRNewswire-USNewswire/ -- She is an African American woman and she is a medical doctor, a researcher for the National Cancer Institute (NCI) at the National institutes of Health. Meet Worta McCaskill-Stevens, MD, one of the key players...

2005-11-15 16:39:54

By Susan Heavey WASHINGTON (Reuters) - Women at high risk for breast cancer who take the well-known drug tamoxifen can reduce their long-term risk of developing the disease, according to a new study released on Tuesday. Researchers found that women who took tamoxifen, sold as a generic and by AstraZeneca Plc under the brand Nolvadex, for up to five years were about 43 percent less likely to get breast cancer than those who took a placebo. Out of 6,681 women taking the drug, 145 have...

2004-11-30 18:00:11

A U.S. study of raloxifene found women had more than a 50 percent reduction in breast cancer incidence beyond the first four years of treatment. The Multiple Outcomes of Raloxifene Evaluation, or MORE trial, found that in postmenopausal women with osteoporosis, four years of raloxifene -- under the brand name Evista -- was associated with a 72 percent reduction in breast cancer incidence compared with a placebo. In the Continuing Outcomes Relevant to Evista, or CORE trial, more than...